Advertisement
Canada markets closed
  • S&P/TSX

    22,069.76
    +62.76 (+0.29%)
     
  • S&P 500

    5,360.79
    +13.80 (+0.26%)
     
  • DOW

    38,868.04
    +69.05 (+0.18%)
     
  • CAD/USD

    0.7269
    +0.0001 (+0.01%)
     
  • CRUDE OIL

    78.11
    +2.58 (+3.42%)
     
  • Bitcoin CAD

    95,796.61
    -41.23 (-0.04%)
     
  • CMC Crypto 200

    1,442.80
    -3.87 (-0.27%)
     
  • GOLD FUTURES

    2,327.30
    +2.30 (+0.10%)
     
  • RUSSELL 2000

    2,031.61
    +5.06 (+0.25%)
     
  • 10-Yr Bond

    4.4690
    +0.0390 (+0.88%)
     
  • NASDAQ

    17,192.53
    +59.40 (+0.35%)
     
  • VOLATILITY

    12.74
    +0.52 (+4.26%)
     
  • FTSE

    8,228.48
    -16.89 (-0.20%)
     
  • NIKKEI 225

    39,038.16
    +354.23 (+0.92%)
     
  • CAD/EUR

    0.6750
    +0.0027 (+0.40%)
     

Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference

FRIENDSWOOD, Texas, May 15, 2024--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 2:00 p.m. Eastern time.

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at ir.castlebiosciences.com/events-presentations/. A replay of the webcast will be available following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

ADVERTISEMENT

Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515189022/en/

Contacts

Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com

Media Contact:
Allison Marshall
amarshall@castlebiosciences.com